AEON Biopharma, Inc. (AEON) Annual Income Statement (USD)
AEON Quarterly Financials (USD)
Frequently Asked Questions About AEON Biopharma, Inc. (AEON) Stock
AEON Biopharma, Inc.'s (AEON) last reported annual revenue was N/A.
AEON Biopharma, Inc.'s (AEON) annual revenue growth rate based on the revenue reported in the past 5 years is : N/A
AEON Biopharma, Inc.'s(AEON) is not profitable as of its last reported annual financials.
The net profit margin for AEON Biopharma, Inc.'s(AEON) from its laster reported year is N/A
The return on equity (ROE) for AEON Biopharma, Inc.'s(AEON) from its last reported annual financials is : 0.00%
The return on assets (ROA) for AEON Biopharma, Inc.'s(AEON) from its last reported annual financials is : -597.69%
The return on invested capital (ROIC) for AEON Biopharma, Inc.'s(AEON) from its last reported annual financials is : 31.22%
The Debt to Equity ratio for AEON Biopharma, Inc.'s(AEON) from its last reported annual financials is : 0.00%
The dividend yield for AEON Biopharma, Inc.'s(AEON) from its laster reported year is 0.00%
AEON Biopharma, Inc.'s(AEON) has negative cash flow as of its last reported annual financials.
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AEON !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
